Dr. Robert Phelps
+49 (0) 89 5480177 - 66
(PresseBox) (Munich , 07.05.2018) BayPAT,
service provider offering services in the area of technology transfer,
IP management and commercialization, today announced that its licensee
Scintomics has signed a sub-license and option agreement with Blue Earth
Diagnostics, Ltd. In July 2017, BayPAT has out-licensed the radiohybrid
PSMA-targeted technology, developed at the Technical University of
Munich (TUM) to Scintomics. As a licensor of Scintomics, BayPAT ab initiowas
involved in the negotiations between Scintomics and Blue Earth
Diagnostics offering support and solution-oriented approaches leading to
fast and straightforward contract signing.
terms of the agreement, Blue Earth Diagnostics has acquired the
exclusive worldwide rights to a broad family of prostate specific
membrane antigen (PSMA)-targeted radiohybrid agents for cancer imaging,
together with an exclusive option to explore therapeutic applications.
The out-licensed rhPSMA pharmaceuticals have potential in both imaging
and therapy of prostate cancer. Blue Earth Diagnostics in close
collaboration with Scintomics, TUM and BayPAT will drive development of a
lead imaging compound, 18F-rhPSMA, and use joint forces to identify
optimized therapeutic candidates for future development.
are very happy that BayPAT could support our licensee Scintomics to lay
the foundation for rhPSMA to become a success story for prostate cancer
patients by finding Blue Earth Diagnostics as an ideal partner for
rapid commercialization of the rhPSMA radiopharmaceuticals.” Dr. Robert
Phelps, BayPAT’s Chief Executive Officer said.
very enthusiastic about the broad applicability of the versatile
radiohybrid technology. It allows, for the very first time, the true
bridging of functional imaging and radioligand therapy by
labeling/activation of either the imaging or therapeutic option, without
affecting a drug’s molecular structure,” said Saskia Kropf, Chief
Executive Officer of Scintomics. In addition, Saskia Kropf is convinced
“that this exciting agreement with Blue Earth Diagnostics on rhPSMAs
will also pave the way for further rh-based targeted ligands for imaging
“This agreement supports our strategic
focus and is the next step in advancing our mission to develop and
deliver products that address unmet medical needs in prostate cancer,”
said Jonathan Allis, D. Phil., CEO of Blue Earth Diagnostics.
was invented at the Technical University of Munich, Germany and
commercialized by BayPAT. At the Technical University of Munich it has
been utilized clinically in the diagnostic imaging of men with both
primary and recurrent prostate cancer. 18F-rhPSMA consists of a
prostate-specific membrane antigen (PSMA) receptor ligand, which
attaches to and is internalized by prostate cancer cells, and is labeled
with the 18F radioisotope for PET imaging. rhPSMA and other “rh”
compounds, can also be labeled with the radioisotope 177Lu for
cancer is the second leading cause of cancer-related death in men.
While most primary prostate cancer can be successfully treated, the
disease recurs in approximately one-third of patients. In some patients,
recurrent disease is detectable only by a rise in prostate specific
antigen (PSA) levels, yet the location of the recurrence cannot
consistently be located by conventional imaging, potentially impacting
subsequent management of these patients.
GmbH was founded in 2006 and initially focused its business on the
development and production of fully automated devices for GMP production
of radiopharmaceuticals at hospitals and clinical sites. As part of
Scintomics natural expansion in providing fully integrated
radiopharmaceutical service, Scintomics has made itself a name worldwide
as a highly specialized company for innovative and unique nuclear
medicine tracer technology, both for imaging and therapy. On the road to
continued expansion, Scintomics considers the radiohybrid tracer
platform as an important milestone in its strategic position as one of
the "global players" in the radiopharmaceutical business. Although the
path through successful clinical studies is not an easy one, the rapid
approval of the first radiohybrid, a rhPSMA tracer, will have highest
priority for Scintomics.
The Bayerische Patentallianz GmbH (BayPAT) was founded in 2007 by the Universities of Bavaria e.V. and the Bavarian Universities of Applied Sciences e.V. as the central patent and marketing agency to foster technology transfer of Bavarian Universities, University Hospitals and Universities of Applied Sciences and is responsible for 33 research institutes. Under the umbrella of the Bavarian Research and Innovation Agency (BayFIA), BayPAT is a full-service technology management provider offering services in the area of technology transfer, IP management and commercialization. Key clients are the Bavarian Universities, University Hospitals and Universities of Applied Sciences and its over 25.000 associated scientists, as well as non-university research institutes, industry, and independent inventors worldwide. Main focus in assessing and exploiting IP are the areas of biotechnology, chemistry, medical engineering, physics, automotive industry, energy and environment engineering, information and communication technology as well as mechanical engineering.
Finden Sie den richtigen Ansprechpartner auf unserer Team-Seite oder benutzen Sie für Ihre Anfrage einfach das Kontakt-Formular.